Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-21. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
== External links == Transporter Classification Database List at qmul.ac.uk Saier MH, Tran CV, Barabote RD (January 2006). "TCDB: the Transporter Classification Database for membrane transport protein analyses and information". Nucleic Acids Res. 34 (Database issue): D181–6. doi:10.1093/nar/gkj001. PMC 1334385. PMID 16381841. Busch W, Saier MH (2002). "The transporter classification (TC) system, 2002". Crit. Rev. Biochem. Mol. Biol. 37 (5): 287–337. doi:10.1080/10409230290771528. PMID 12449427. S2CID 10558982. Classification of human transporters in pharmacology
Having in mind the constitutional position of the Bohemian Crown and being conscious of the glory and power which that Crown has given us and our predecessors… we gladly recognise the rights of the kingdom and are prepared to renew that recognition through our coronation oath. For the planned coronation, the composer Bedřich Smetana had written the opera Libuše, but the ceremony did not take place. The creation of the German Empire, domestic opposition from German-speaking liberals (especially German-Bohemians) and from Hungarians doomed the Fundamental Articles. Hohenwart resigned and nothing changed. Many Czech people were waiting for political changes in monarchy, including Tomáš Garrigue Masaryk and others. Masaryk served in the Reichsrat (Upper House) from 1891 to 1893 in the Young Czech Party and again from 1907 to 1914 in the Realist Party (which he had founded in 1900), but he did not campaign for the independence of Czechs and Slovaks from Austria-Hungary. In Vienna in 1909 he helped Hinko Hinković's defense in the fabricated trial against prominent Croats and Serbs members of the Serbo-Croatian Coalition (such as Frano Supilo and Svetozar Pribićević), and others, who were sentenced to more than 150 years and a number of death penalties. The Bohemian question would remain unresolved for the entirety of Franz Joseph's reign.
=== Biochemistry === Iron acquisition poses a problem for aerobic organisms because ferric iron is poorly soluble near neutral pH. Thus, these organisms have developed means to absorb iron as complexes, sometimes taking up ferrous iron before oxidising it back to ferric iron. In particular, bacteria have evolved very high-affinity sequestering agents called siderophores. After uptake in human cells, iron storage is precisely regulated. A major component of this regulation is the protein transferrin, which binds iron ions absorbed from the duodenum and carries it in the blood to cells. Transferrin contains Fe3+ in the middle of a distorted octahedron, bonded to one nitrogen, three oxygens and a chelating carbonate anion that traps the Fe3+ ion: it has such a high stability constant that it is very effective at taking up Fe3+ ions even from the most stable complexes. At the bone marrow, transferrin is reduced from Fe3+ to Fe2+ and stored as ferritin to be incorporated into hemoglobin. The most commonly known and studied bioinorganic iron compounds (biological iron molecules) are the heme proteins: examples are hemoglobin, myoglobin, and cytochrome P450. These compounds participate in transporting gases, building enzymes, and transferring electrons. Metalloproteins are a group of proteins with metal ion cofactors. Some examples of iron metalloproteins are ferritin and rubredoxin. Many enzymes vital to life contain iron, such as catalase, lipoxygenases, and IRE-BP.
Sources: en.wikipedia.org
Starbucks did not market Teavana products in its stores, though the acquisition allowed the expansion of Teavana beyond shopping malls. In January 2015, Starbucks began to roll out Teavana teas into Starbucks stores, both in to-go beverage and retail formats. In November 2017, Starbucks sold Tazo to Unilever for $384 million. Starbucks shut down Teavana in early 2018.
The plasma pH can be altered by respiratory changes in the partial pressure of carbon dioxide; or altered by metabolic changes in the carbonic acid to bicarbonate ion ratio. The bicarbonate buffer system regulates the ratio of carbonic acid to bicarbonate to be equal to 1:20, at which ratio the blood pH is 7.4 (as explained in the Henderson–Hasselbalch equation). A change in the plasma pH gives an acid–base imbalance. In acid–base homeostasis there are two mechanisms that can help regulate the pH. Respiratory compensation a mechanism of the respiratory center, adjusts the partial pressure of carbon dioxide by changing the rate and depth of breathing, to bring the pH back to normal. The partial pressure of carbon dioxide also determines the concentration of carbonic acid, and the bicarbonate buffer system can also come into play. Renal compensation can help the bicarbonate buffer system. The sensor for the plasma bicarbonate concentration is not known for certain. It is very probable that the renal tubular cells of the distal convoluted tubules are themselves sensitive to the pH of the plasma. The metabolism of these cells produces carbon dioxide, which is rapidly converted to hydrogen and bicarbonate through the action of carbonic anhydrase. When the ECF pH falls (becoming more acidic) the renal tubular cells excrete hydrogen ions into the tubular fluid to leave the body via urine. Bicarbonate ions are simultaneously secreted into the blood that decrease the carbonic acid, and consequently raise the plasma pH.
Four drugs from the class of direct Xa inhibitors are marketed worldwide. Rivaroxaban (Xarelto) was the first approved FXa inhibitor to become commercially available in Europe and Canada in 2008. The second one was apixaban (Eliquis), approved in Europe in 2011 and in the United States in 2012. The third one edoxaban (Lixiana, Savaysa) was approved in Japan in 2011 and in Europe and the US in 2015. Betrixaban (Bevyxxa) was approved in the US in 2017.
The other two electric utility companies in the country are Sarawak Energy and Sabah Electricity. In 2013, Malaysia's total power generation capacity was over 29,728 megawatts. Total electricity generation was 140,985.01 GWh and total electricity consumption was 116,087.51 GWh. Energy production in Malaysia is largely based on oil and natural gas, owing to Malaysia's oil and natural gas reserves, which are the fourth largest in the Asia-Pacific region.
Sources: en.wikipedia.org
confluence Also confluency. In cell culture, a measure of the proportion of the surface area of a culture vessel that is covered by adherent cells, commonly expressed as a percentage. A culture in which the entire surface is completely covered by a continuous monolayer, such that all cells are immediately adjacent to and in direct physical contact with other cells, with no gaps or voids, is said to be 100-percent confluent. Different cell lines may exhibit differences in morphology, growth rate, or gene expression depending on the degree of confluence. Because of contact inhibition, most show a significant reduction in the rate of cell division as they approach complete confluence, though some immortalized cells may continue to divide, expanding vertically rather than horizontally by stacking themselves on top of the parent cells, until all available nutrients are depleted.
=== The assembly of proteinoids into microspheres === Fox claims that the origin of the cell is a microsphere or protocell. Microspheres are made from the addition of water or salt solution to the appropriate proteinoids. To prepare microspheres, Fox added 10 mL of boiling salt solution to the hot proteinoids and stirred carefully. Then, he boiled the solution for thirty seconds, removed the solution from its vessel, and poured it into a cool vessel. When the solution was cooled, he observed the results under a microscope. One gram of protein polymer yields up to one billion microspheres with about ten billion molecules of proteinoid in each sphere. Fox says that the assembly of microspheres takes about twenty minutes and is more immediate and produces better microspheres if the water (or salt solution) is heated prior to mixing. Microspheres have multiple properties that are similar to those of cells. The microspheres produced were mostly uniformly spherical and Fox believed that the shape and uniformity mimics that of coccoid bacteria. He also believed that the uniformity meant that there was a sophisticated system that kept the microspheres at equilibrium. The microspheres were able to asexually divide via binary fission, could form junctions with other microspheres, and developed a double membrane corresponding to that of a cell.
== Poiseuille flow through some non-circular cross-sections == Joseph Boussinesq derived the velocity profile and volume flow rate in 1868 for rectangular channel and tubes of equilateral triangular cross-section and for elliptical cross-section. Joseph Proudman derived the same for isosceles triangles in 1914. Let G = −dp/dx be the constant pressure gradient acting in direction parallel to the motion. The velocity and the volume flow rate in a rectangular channel of height 0 ≤ y ≤ h and width 0 ≤ z ≤ l are
When cells on one side of a stem grow longer and faster than cells on the other side, the stem will bend to the side of the slower growing cells as a result. This directional growth can occur via a plant's response to a particular stimulus, such as light (phototropism), gravity (gravitropism), water, (hydrotropism), and physical contact (thigmotropism). Plant growth and development are mediated by specific plant hormones and plant growth regulators (PGRs) (Ross et al. 1983). Endogenous hormone levels are influenced by plant age, cold hardiness, dormancy, and other metabolic conditions; photoperiod, drought, temperature, and other external environmental conditions; and exogenous sources of PGRs, e.g., externally applied and of rhizospheric origin.
==== iLet Bionic Pancreas ==== The iLet Bionic Pancreas system, developed by Beta Bionics, is an automated insulin delivery system comprising the iLet ACE Pump, the iLet Dosing Decision Software, and a compatible continuous glucose monitor — either the Dexcom G6/G7 or the FreeStyle Libre 3 Plus sensor. The system is designed to automate insulin dosing with minimal user input, relying solely on the user’s body weight for initialization. It utilizes three algorithms to manage insulin delivery: a basal insulin controller, which adjusts basal rates every five minutes based on current glucose values, glucose trends, and historical CGM data; a bolus correction controller, which incorporates insulin on board in addition to these factors to calculate correction doses; and a meal announcement controller, which determines bolus doses according to the user’s estimation of meal size. The system does not require user-programmed basal rates, insulin-to-carbohydrate ratios, or correction factors. It supports three glucose targets—110, 120, or 130 mg/dL—and is approved for use in individuals aged six years and older with type 1 diabetes.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.